比较四种胰岛素抵抗替代指标与非肥胖成人MASLD的关系
Comparison of four insulin resistance surrogate indices for incident MASLD in Chinese and prevalent MASLD in Japanese nonobese adults
研究比较了四种胰岛素抵抗替代指标(TyG、TyG-BMI、METS-IR、SPISE)与非肥胖成人代谢功能障碍相关脂肪性肝病(MASLD)的关系。在纵向中国队列中,TyG-BMI与MASLD的关联最强,AUC最高;在横断面日本队列中,TyG-BMI、METS-IR和SPISE均优于BMI。
- Article
- Open access
- Published: 04 November 2026
Scientific Reports (2026) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Insulin resistance (IR) is central to metabolic dysfunction-associated steatotic liver disease (MASLD), but head-to-head comparisons of IR surrogate indices in nonobese populations are scarce. We compared the triglyceride-glucose index (TyG), TyG-body mass index (TyG-BMI), metabolic score for insulin resistance (METS-IR) and single-point insulin sensitivity estimator (SPISE) in relation to incident MASLD in a longitudinal Chinese cohort and prevalent MASLD in a cross-sectional Japanese cohort of nonobese adults. We analyzed two Dryad health examination datasets with different designs. The Chinese cohort (n = 16,172) was longitudinal: participants free of hepatic steatosis at baseline were followed for a median of 35.8 months (interquartile range [IQR] 23.4–47.3), the outcome was incident MASLD, and entry was restricted to low-density lipoprotein cholesterol (LDL-C) ≤ 3.12 mmol/L. The Japanese NAGALA cohort (n = 12,932) was cross-sectional: prevalent MASLD was ascertained at the baseline examination, and entry was restricted to fasting blood glucose (FBG) < 6.1 mmol/L. The Japanese cohort was used for replication rather than harmonized external validation, and all participants had BMI < 25 kg/m². Steatosis was defined by ultrasound and MASLD by the 2023 multisociety criteria. Associations were examined with multivariable logistic regression and restricted cubic splines, together with a Cox proportional-hazards sensitivity analysis of the Chinese follow-up data; discrimination was assessed with the area under the receiver operating characteristic curve (AUC), DeLong tests, category-free net reclassification improvement (NRI), integrated discrimination improvement (IDI), decision curve analysis and bootstrap validation. Sensitivity analyses addressed the overlap between index components and the MASLD criteria by using steatosis alone as the outcome and excluding cases qualifying only through shared criteria. Incident MASLD developed in 2,114 (13.1%) Chinese participants during follow-up, and prevalent MASLD was present in 1,132 (8.8%) Japanese participants. Fully adjusted odds ratios per standard deviation increase in TyG, TyG-BMI, METS-IR and SPISE were 2.39, 5.09, 3.65 and 0.15 in the Chinese cohort and 2.19, 3.71, 2.90 and 0.18 in the Japanese cohort (all P < 0.001); the corresponding hazard ratios in the Cox sensitivity analysis were 1.83, 3.25, 2.10 and 0.24 (all P < 0.001), and associations were attenuated but persisted in sensitivity analyses. TyG-BMI had the highest AUC (0.8755 and 0.8865), and TyG-BMI, METS-IR and SPISE each outperformed BMI (0.8248 and 0.8404; DeLong P < 0.001), whereas TyG did not. Adding each index to a baseline model of total cholesterol, triglycerides, FBG and BMI improved NRI and IDI but increased the AUC by at most 0.0078, a gain that became negligible when HDL-C was added to the baseline model and when the components were modeled flexibly; decision curve analysis showed no clinically meaningful difference in net benefit, and NRI gains should therefore be interpreted cautiously. In nonobese adults, BMI-integrated IR indices, particularly TyG-BMI, were associated with incident MASLD in the longitudinal Chinese cohort and with prevalent MASLD in the cross-sectional Japanese cohort, and discriminated both outcomes better than single anthropometric or biochemical markers (BMI, fasting glucose and triglycerides), whereas TyG alone did not outperform BMI. Because the two cohorts differ in design and outcome, their estimates should not be compared numerically. Shared diagnostic variables may inflate these estimates, and the incremental gains were small, so prospective external validation is required before any clinical use.
Abbreviations
- MASLD:
-
metabolic dysfunction-associated steatotic liver disease
- TyG:
-
triglyceride-glucose index
- TyG-BMI:
-
triglyceride-glucose-body mass index
- METS-IR:
-
metabolic score for insulin resistance
- SPISE:
-
single-point insulin sensitivity estimator
- IR:
-
insulin resistance
- ROC:
-
receiver operating characteristic
- AUC:
-
area under the receiver operating characteristic curve
- NRI:
-
net reclassification improvement
- IDI:
-
integrated discrimination improvement
- RCS:
-
restricted cubic spline
- FBG:
-
fasting blood glucose
- HDL-C:
-
high-density lipoprotein cholesterol
- BMI:
-
body mass index
- FDR:
-
false discovery rate
Acknowledgements
We thank the Dryad repository and the original investigators for providing open access to the datasets used in this study.
Funding
Not applicable.
Author information
Authors and Affiliations
Department of Endocrinology, Second Affiliated Hospital of Jilin University, No. 4026, Yatai Street, Nanguan District, Changchun, 130041, Jilin, China
Junwen Mao, Jing Kang, Bing Han & Yanjun Wang
Authors
- Junwen Mao
- Jing Kang
- Bing Han
- Yanjun Wang
Corresponding author
Correspondence to Yanjun Wang.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval and consent to participate
This study was approved by the Ethics Committee of Wenzhou People’s Hospital and the Ethics Committee of Murakami Memorial Hospital. All study procedures adhere to the Declaration of Helsinki. All participants provided written informed consent. Furthermore, all data were anonymized, eliminating the need for renewed informed consent. As a secondary analysis of the original study, this research involved only the extraction and analysis of existing data without any modification to the original dataset. All de-identified raw cohort data analyzed in this study are publicly accessible via the Dryad database at https://datadryad.org, with DOIs cited within the manuscript.
Consent for publication
All authors gave their consent for publication.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Mao, J., Kang, J., Han, B. et al. Comparison of four insulin resistance surrogate indices for incident MASLD in Chinese and prevalent MASLD in Japanese nonobese adults. Sci Rep (2026). https://doi.org/10.1038/s41598-026-78533-y
Received: 21 August 2026
Accepted: 27 October 2026
Published: 04 November 2026
DOI: https://doi.org/10.1038/s41598-026-78533-y
Keywords
来源:Nature 健康护理主题 · nature.com